Advances in bronchopulmonary dysplasia

References

• Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379(9832):2162-72
   PubMed Web of Science ®Google Scholar
• Lee SK, Ye XY, Singhal N, et al. Higher altitude and risk of bronchopulmonary dysplasia among preterm infants. Am J Perinatol 2013;30(7):601-6
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Early Treatment Prevents Lasting Breathing Problems in Some Premature Babies. Available from: http://www.nhlbi.nih.gov/news/press-releases/2006/early-treatment-prevents-lasting-breathing-problems-in-some-premature-babies.html
   Google Scholar
• Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276(7):357-68
   PubMed Web of Science ®Google Scholar
• Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82(4):527-32
   PubMed Web of Science ®Google Scholar
• Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163(7):1723-9
   PubMedGoogle Scholar
• Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116(6):1353-60
   PubMed Web of Science ®Google Scholar
• Walsh MC, Wilson-Costello D, Zadell A, et al. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003;23(6):451-6
   PubMedGoogle Scholar
• Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004;114(5):1305-11
   PubMed Web of Science ®Google Scholar
• Van Marter LJ. Epidemiology of bronchopulmonary dysplasia. Semin Fetal Neonatal Med 2009;14(6):358-66
   PubMed Web of Science ®Google Scholar
• Carraro S, Filippone M, Da Dalt L, et al. Bronchopulmonary dysplasia: the earliest and perhaps the longest lasting obstructive lung disease in humans. Early Hum Dev 2013;89(Suppl 3):S3-5
   Google Scholar
• Berkelhamer SK, Mestan KK, Steinhorn RH. Pulmonary hypertension in bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):124-31
   PubMed Web of Science ®Google Scholar
• Schmidt B, Asztalos EV, Roberts RS, et al. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003;289(9):1124-9
   PubMed Web of Science ®Google Scholar
• Walsh MC, Morris BH, Wrage LA, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 2005;146(6):798-804
   PubMed Web of Science ®Google Scholar
• Natarajan G, Pappas A, Shankaran S, et al. Outcomes of extremely low birth weight infants with bronchopulmonary dysplasia: impact of the physiologic definition. Early Hum Dev 2012;88(7):509-15
   PubMed Web of Science ®Google Scholar
• Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr 2013;25(3):329-37
   Google Scholar
• Bhandari A, McGrath-Morrow S. Long-term pulmonary outcomes of patients with bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):132-7
   PubMed Web of Science ®Google Scholar
• Gunville CF, Sontag MK, Stratton KA, et al. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr 2010;157(2):209-14; e1
   Google Scholar
• Vom Hove M, Prenzel F, Uhlig HH, Robel-Tillig E. Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: a case-control follow-up at school age. J Pediatr 2014;164(1):40-5; e4
   Google Scholar
• Fawke J, Lum S, Kirkby J, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010;182(2):237-45
   PubMed Web of Science ®Google Scholar
• Welsh L, Kirkby J, Lum S, et al. The EPICure study: maximal exercise and physical activity in school children born extremely preterm. Thorax 2010;65(2):165-72
   Google Scholar
• Clemm H, Roksund O, Thorsen E, et al. Aerobic capacity and exercise performance in young people born extremely preterm. Pediatrics 2012;129(1):e97-e105
   Google Scholar
• Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J 2008;32(2):321-8
   Google Scholar
• Narayanan M, Beardsmore CS, Owers-Bradley J, et al. Catch-up alveolarization in ex-preterm children: evidence from (3)He magnetic resonance. Am J Respir Crit Care Med 2013;187(10):1104-9
   Google Scholar
• Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007;357(19):1946-55
   PubMed Web of Science ®Google Scholar
• Shah PS, Sankaran K, Aziz K, et al. Outcomes of preterm infants <29 weeks gestation over 10-year period in Canada: a cause for concern? J Perinatol 2012;32(2):132-8
   PubMed Web of Science ®Google Scholar
• Jobe AH. What is BPD in 2012 and what will BPD become? Early Hum Dev 2012;88(Suppl 2):S27-8
   Google Scholar
• Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. Semin Perinatol 2003;27(4):281-7
   PubMed Web of Science ®Google Scholar
• Payne NR, Finkelstein MJ, Liu M, et al. NICU practices and outcomes associated with 9 years of quality improvement collaboratives. Pediatrics 2010;125(3):437-46
   Web of Science ®Google Scholar
• Tommiska V, Heinonen K, Lehtonen L, et al. No improvement in outcome of nationwide extremely low birth weight infant populations between 1996-1997 and 1999-2000. Pediatrics 2007;119(1):29-36
   PubMed Web of Science ®Google Scholar
• Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics 2000;106(5):1070-9
   PubMed Web of Science ®Google Scholar
• Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(3):217-24
   Google Scholar
• Ghanta S, Tropea Leeman K, Christou H. An update on pharmacologic approaches to bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):115-23
   Google Scholar
• Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatr 2011;170(9):1097-105
   PubMed Web of Science ®Google Scholar
• Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010(12):CD000139
   Google Scholar
• Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354(20):2112-21
   PubMed Web of Science ®Google Scholar
• Davis PG, Schmidt B, Roberts RS, et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr 2010;156(3):382-7
   PubMed Web of Science ®Google Scholar
• Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012;307(3):275-82
   PubMed Web of Science ®Google Scholar
• Demauro SB, Dysart K, Kirpalani H. Stopping the swinging pendulum of postnatal corticosteroid use. J Pediatr 2014;164(1):9-11
   Google Scholar
• Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2010(1):CD001146
   Google Scholar
• Nixon PA, Washburn LK, Schechter MS, O’Shea TM. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. J Pediatr 2007;150(4):345-50
   Google Scholar
• Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350(13):1304-13
   Google Scholar
• O’Shea TM, Washburn LK, Nixon PA, Goldstein DJ. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics 2007;120(3):594-602
   Google Scholar
• Jefferies AL. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatr Child Health 2012;17(10):573-4
   Google Scholar
• Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009(1):CD001145
   Google Scholar
• Watterberg KL; American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010;126(4):800-8
   PubMed Web of Science ®Google Scholar
• DeCastro M, El-Khoury N, Parton L, et al. Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study. J Perinatol 2009;29(4):297-304
   Google Scholar
• Andre P, Thebaud B, Odievre MH, et al. Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease. Intensive Care Med 2000;26(10):1496-500
   Google Scholar
• Parikh NA, Kennedy KA, Lasky RE, et al. Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. J Pediatr 2013;162(4):685-90; e1
   Google Scholar
• Kersbergen KJ, de Vries LS, van Kooij BJM, et al. Hydrocortisone Treatment for Bronchopulmonary Dysplasia and Brain Volumes in Preterm Infants. J Pediatr 2013;163(3):666-71; e1
   Google Scholar
• Inder TE, Benders M. Postnatal Steroids in the Preterm Infant—the Good, the Ugly, and the Unknown. J Pediatr 2013;162(4):667-70
   Google Scholar
• Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(2):111-17
   Google Scholar
• Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114(6):1649-57
   Web of Science ®Google Scholar
• Onland W, Offringa M, Cools F, et al. Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial. BMC Pediatr 2011;11:102
   PubMed Web of Science ®Google Scholar
• Kirpalani H, Millar D, Lemyre B, et al. A trial comparing noninvasive ventilation strategies in preterm infants. N Engl J Med 2013;369(7):611-20
   PubMed Web of Science ®Google Scholar
• Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008;358(7):700-8
   PubMed Web of Science ®Google Scholar
• SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Finer NN, Carlo WA, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362(21):1970-9
   PubMed Web of Science ®Google Scholar
• Sandri F, Plavka R, Ancora G, et al. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 2010;125(6):e1402-9
   Web of Science ®Google Scholar
• Dunn MS, Kaempf J, de Klerk A, et al. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics 2011;128(5):e1069-76
   PubMed Web of Science ®Google Scholar
• Schmolzer GM, Kumar M, Pichler G, et al. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ 2013;347:f5980
   PubMed Web of Science ®Google Scholar
• Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007(4):CD003063
   Google Scholar
• Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2012;3:CD000510
   Google Scholar
• Tang S, Zhao J, Shen J, et al. Nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure in neonates: a systematic review and meta-analysis. Indian Pediatr 2013;50(4):371-6
   Google Scholar
• Peng W, Zhu H, Shi H, Liu E. Volume-targeted ventilation is more suitable than pressure-limited ventilation for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2014;99(2):F158-65
   Web of Science ®Google Scholar
• Wheeler KI, Klingenberg C, Morley CJ, Davis PG. Volume-targeted versus pressure-limited ventilation for preterm infants: a systematic review and meta-analysis. Neonatology 2011;100(3):219-27
   Google Scholar
• Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology 2013;105(1):55-63
   Google Scholar
• Saugstad OD, Ramji S, Soll RF, Vento M. Resuscitation of newborn infants with 21 or 100% oxygen: an updated systematic review and meta-analysis. Neonatology 2008;94(3):176-82
   Web of Science ®Google Scholar
• Kapadia VS, Chalak LF, Sparks JE, et al. Resuscitation of preterm neonates with limited versus high oxygen strategy. Pediatrics 2013;132(6):e1488-96
   Web of Science ®Google Scholar
• Vento M, Moro M, Escrig R, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. Pediatrics 2009;124(3):e439-49
   PubMed Web of Science ®Google Scholar
• Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology 2013;103(4):353-68
   PubMed Web of Science ®Google Scholar
• Clyman RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):102-7
   PubMed Web of Science ®Google Scholar
• Kugelman A, Durand M. A comprehensive approach to the prevention of bronchopulmonary dysplasia. Pediatr Pulmonol 2011;46(12):1153-65
   Google Scholar
• Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009;154(6):873-6
   PubMed Web of Science ®Google Scholar
• Peliowski A; Canadian Paediatric Society, Fetus and Newborn Committee. Inhaled nitric oxide use in newborns. Paediatr Child Health 2012;17(2):95-100
   Google Scholar
• Afshar S, Gibson LL, Yuhanna IS, et al. Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003;284(5):L749-58
   Google Scholar
• Raffay TM, Martin RJ, Reynolds JD. Can nitric oxide-based therapy prevent bronchopulmonary dysplasia? Clin Perinatol 2012;39(3):613-38
   Google Scholar
• Ghanta S, Tropea Leeman K, Christou H. An update on pharmacologic approaches to bronchopulmonary dysplasia. Semin Perinatol 2013;37(2):115-23
   Google Scholar
• Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2010(12):CD000509
   Google Scholar
• Donohue PK, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011;127(2):e414-22
   PubMed Web of Science ®Google Scholar
• Cole FS, Alleyne C, Barks JD, et al. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 2011;127(2):363-9
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns, National Heart, Lung and Blood Institute. Available from: http://clinicaltrials.gov/ct2/show/NCT00955487?term=nitric+oxide+AND+bronchopulmonary+dysplasia&rank=6
   Google Scholar
• Clinicaltrials.gov. Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants, INO Therapeutics. Available from: http://clinicaltrials.gov/ct2/show/NCT00931632?term=nitric+oxide+AND+bronchopulmonary+dysplasia&rank=2
   Google Scholar
• Levesque BM, Kalish LA, LaPierre J, et al. Impact of implementing 5 potentially better respiratory practices on neonatal outcomes and costs. Pediatrics 2011;128(1):e218-26
   Web of Science ®Google Scholar
• Clinicaltrials.gov. The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia, Ajou University School of Medicine. Available from: http://clinicaltrials.gov/ct2/show/NCT01717625?term=montelukast+in+very+low+birth+weight+infants&rank=2
   Google Scholar
• Howlett A, Ohlsson A, Plakkal N. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2012;3:CD000366
   PubMedGoogle Scholar
• Clinicaltrials.gov. Multidose pharmacokinetics and dose ranging of inositol in premature infants (INS-2), Eunice Kennedy Shriver National Institute of Child Health and Human Development. Available from: http://clinicaltrials.gov/ct2/show/NCT01030575?term=inositol+AND+BPD&rank=1
   Google Scholar
• Mactier H, Weaver LT. Vitamin A and preterm infants: what we know, what we don’t know, and what we need to know. Arch Dis Child Fetal Neonatal Ed 2005;90(2):F103-8
   Google Scholar
• Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2011(10):CD000501
   Google Scholar
• James ML, Ross AC, Nicola T, et al. VARA attenuates hyperoxia-induced impaired alveolar development and lung function in newborn mice. Am J Physiol Lung Cell Mol Physiol 2013;304(11):L803-12
   Google Scholar
• Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999;340(25):1962-8
   PubMed Web of Science ®Google Scholar
• Ambalavanan N, Tyson JE, Kennedy KA, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 2005;115(3):e249-54
   Google Scholar
• Moreira A, Caskey M, Fonseca R, et al. Impact of providing vitamin A to the routine pulmonary care of extremely low birth weight infants. J Matern Fetal Neonatal Med 2012;25(1):84-8
   PubMed Web of Science ®Google Scholar
• Meyer S, Gortner L; NeoVitaA Trial Investigators. Early postnatal additional high-dose oral vitamin a supplementation versus placebo for 28 Days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. Neonatology 2014;105(3):182-8
   Web of Science ®Google Scholar
• Berggren E, Liljedahl M, Winbladh B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 2000;89(4):460-4
   Web of Science ®Google Scholar
• Abdel-Latif ME, Osborn DA. Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev 2012;10:CD008310
   Google Scholar
• Dargaville PA, Aiyappan A, De Paoli AG, et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed 2013;98(2):F122-6
   PubMed Web of Science ®Google Scholar
• Lista G, Fontana P, Castoldi F, et al. Does sustained lung inflation at birth improve outcome of preterm infants at risk for respiratory distress syndrome? Neonatology 2011;99(1):45-50
   Web of Science ®Google Scholar
• Hillman NH, Kemp MW, Noble PB, et al. Sustained inflation at birth did not protect preterm fetal sheep from lung injury. Am J Physiol Lung Cell Mol Physiol 2013;305(6):L446-53
   Google Scholar
• Dani C, Lista G, Pratesi S, et al. Sustained lung inflation in the delivery room in preterm infants at high risk of respiratory distress syndrome (SLI STUDY): study protocol for a randomized controlled trial. Trials 2013;14:67
   PubMed Web of Science ®Google Scholar
• Assessment of Lung Aeration at Birth, University of Alberta, Canada. Available from: http://clinicaltrials.gov/ct2/show/NCT01739114?term=sustained+inflation+AND+bronchopulmonary+dysplasia&rank=1
   Google Scholar
• Colaizy TT, Younis UM, Bell EF, Klein JM. Nasal high-frequency ventilation for premature infants. Acta Paediatr 2008;97(11):1518-22
   PubMed Web of Science ®Google Scholar
• Non-invasive Ventilation for Extubation Success in Infants Less Than 1,500 Grams (NOVEL), Mount Sinai Hospital, Canada. Available from: http://clinicaltrials.gov/ct2/show/NCT02051491?term=non-invasive+high+frequency&rank=1
   Google Scholar
• Tolerance to nHFPV Versus nCPAP in Neonatal Respiratory Distress (TONIPEP), University Hospital, Bordeaux. Available from: http://clinicaltrials.gov/ct2/show/NCT02030691?term=non-invasive+high+frequency&rank=2
   Google Scholar
• van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009;180(11):1131-42
   PubMed Web of Science ®Google Scholar
• Blaisdell CJ, Gail DB, Nabel EG. National Heart, Lung, and Blood Institute perspective: lung progenitor and stem cells--gaps in knowledge and future opportunities. Stem Cells 2009;27(9):2263-70
   Google Scholar
• O’Reilly M, Thébaud B. Using cell-based strategies to break the link between bronchopulmonary dysplasia and the development of chronic lung disease in later life. Pulm Med 2013;2013:874161
   Google Scholar
• Borghesi A, Cova C, Gazzolo D, Stronati M. Stem cell therapy for neonatal diseases associated with preterm birth. J Clin Neonatol 2013;2(1):1-7
   Google Scholar
• Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant 2012;47(2):164-71
   PubMed Web of Science ®Google Scholar
• Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009;180(11):1122-30
   PubMed Web of Science ®Google Scholar
• Tropea KA, Leder E, Aslam M, et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012;302(9):829-37
   PubMed Web of Science ®Google Scholar
• Zhang H, Fang J, Su H, et al. Bone marrow mesenchymal stem cells attenuate lung inflammation of hyperoxic newborn rats. Pediatr Transplant 2012;16(6):589-98
   Google Scholar
• Fung ME, Thebaud B. Stem cell-based therapy for neonatal lung disease: it is in the juice. Pediatr Res 2014;75:2-7
   PubMed Web of Science ®Google Scholar
• Pierro M, Ionescu L, Montemurro T, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013;68(5):475-84
   PubMed Web of Science ®Google Scholar
• Chang YS, Choi SJ, Sung DK, et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2011;20(11-12):1843-54
   PubMed Web of Science ®Google Scholar
• Ahn S, Chang Y, Kim E, et al. Human umbilical cord blood derived mensenchymal stem cells transplantation for bronchopulmonary dysplasia: results of a phase I dose escalation clinical study. Pediatric Academic Societies Annual Meeting. Washington DC;2013
   Google Scholar
• Clinicaltrials.gov. Efficacy and safety evaluation of Pneumostem versus a control group for treatment of BPD in premature infants, Medipost Co Ltd. Available from: http://clinicaltrials.gov/ct2/show/NCT01828957?term=BPD+pneumostem&rank=1
   Google Scholar
• Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J 2013;41(4):966-73
   PubMed Web of Science ®Google Scholar
• Dayanim S, Lopez B, Maisonet TM, et al. Caffeine induces alveolar apoptosis in the hyperoxia-exposed developing mouse lung. Pediatr Res 2014;75:395-402
   Google Scholar